CoaguChek®

Literatura

V případě zájmu o jakoukoliv z uvedených publikací kontaktujte Roche Diagnostice.

I. Posouzení funkčních vlastností systému CoaguChek.

  1. van den Bessclaar AMHP, Breddin K, Lutze G, Parker-Wiliams J, Taborski U, Vogel G, Tritschler W, Zerback R, Leinberger R: Multicenter evaluation of a new capillary blood prothrombin time monitoring system. Blood Coagul Fibrinol 1995; 6: 726-732.
  2. Kapiotis, S, Quehenberger P, Speiser W: Evaluation of the new metod CoaguChek® for the determination of prothrombin time from capillary blood: comparison with thrombotest on KC-1. Thromb. Res 1995; 77: 563-567.
  3. Kaatz SS, White RH, Hill J, Mascha E, Humphries, JE, Becker DM: Accuracy of laboratory and portable monitor international normalized ratio determinations. Arch Intern Med 1995; 155: 1861-1867.
  4. Müller-Beißenhirtz W, Deikert F, Lang H, Schöndorf T, Spanuth E, Taborski U, Witt I: Selbstkontrolle der oralen Antikoagulation: Standortbestimmung, J Lab Med 1997; 21:556-562.
  5. Doukets JD, Lane A, Milne J, Ginsberg JS: Accuracy of a portable international
  6. normalization ratio monitor in outpatients receiving long-term oral anticoagulant therapy: Comparison with a laboratory reference standard using clinically relevant criteria for agreement. Thromb res 1998; 92: 11-17.
  7. Vacas M, Lafuente PJ, Cuesta S, Iriarte JA: Comparative study of a portable monitor for prothrombin time determination, CoaguChek®, with three systems for control of oral anticoagulation treatment. Haemostasis 1998; 28: 321-328.
  8. Attermann J, Kynde K, Hasenkam JM: Precision of patiens´measurements of the international normalized ratio (INR) using a patient operated whole blood home coagulometer. Thromb Res 1998; 92: 287-291.
  9. Zerback R, Horstkotte D: Patienten-Selbstkontrolle in der Überwachung der Antikoagulantien-Dauertherapie. Z Kardiol 1998; 87: 68-74.
  10. Marzinotto V, Mongale P, Chan A, Adams M, Massicotte P, Leaker M, Andrew M: Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting. Pediatr Cardiol 2000; 21: 347-352.
  11. van der Besselaar AHMP:A comparison of INRs determined with a whole blood prothrombin time device and two international reference preparations for thromboplastin. Thromb Haemost 2000; 84: 410-412.

II. Klinické aspekty self-monitoringu.

  1. Bernardo A: Post-conference session: Experience with patient self-management of oral anticoagulation. J Thromb Thrombolysis 1996; 321-325.
  2. Hasenkam JM, Kimose HH, Knudsen L, Gronncsby H, Halborg J, Christensen TD, Atterman J, Pilegard HK: Self management of oral anticoagulant therapy after heart valve replacement. Eur J Cardio-thorac Surg 1997; 11: 935-942.
  3. Horstkotte D, Piper C, Wiemer M: Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis 1998; 5 (Suppl. 1): 19-24.
  4. Sawicky PT: A structured teaching and self-management program for patients receiving oral anticoagulation. a randomized controlled trial. JAMA 1999; 281: 145-150.
  5. Taborski U, Müller-Berghaus G: State-of-the-Art patient self-management for control of oral anticoagulation. Sem Thromb Hemmostas 1999; 25: 43-48.
  6. Watzke HH, Forberg E, Svolba G, Jimenez-Boj E, Krinninger B: A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. Thromb Haemost 2000; 83: 651-665.
  7. Koertke H, Mizumi K, Bahaktaris A, Wagner O, Koerfer R: INR self-management following mechanical heart valve replacement. J Thromb Thrombolysis 2000; 9: 41-45.
  8. Heldinger KS, Bernardo A, Taborski U, Müller-Berghaus G: Clinical outcome of self-management of oral anticoagulation patients with atrial fibrillation or deep vein thrombosis. Thromb Res 2000; 98: 287-293.
  9. Cromheecke ME, Levi M, Colly LP, de Mol BJM, Prins MH, Hutten BA, Mak R, Keyzers KCJ, Büller HR: Oral anticoagulation self-management and management by a spesialist anticoagulation clinic a randomised cross-over comparison. Lancet 2000; 356: 97-102.
  10. Tripodi A: Control of oral anticoagulant therapy with whole blood prothrombin time devices: the future has begun. Thromb Haemost 2000; 84: 362-363.

III. Ekonomická hlediska

  1. 1.Ansell JE: The value of a specialized program for the management of oral anticoagulation. Hämostaseologic 1997; 17: 133-136.
  2. 2.Taborski U, Wittsamm F-J, Bernardo A: Cost-effectiveness of self-managed anticoagulant therapy in Germany. Sem Thromb Hemostas 1999; 25: 103-109.
  3. 3.Elston Lafata J, Martin SA, Kaatz S, Ward RE: Anticoagulation clinics and patient selftesting for patients on chronic Warfarin therapy: A cost-effectiveness analysis. J Thromb Thrombolysis 2000; 9: S13-S1

1996 - 2008 © Roche s.r.o., Diagnostics Division, Česká republika | právní stanovisko | webmaster